Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

Stopped early · Phase 3

Conditions studied: COVID, Infectious Disease

In brief

In this study, investigators will determine whether the early addition of HT-CCP to standard treatment improves the clinical outcome (as assessed by the Modified WHO Ordinal Scale) of patients with COVID-19 who are hospitalized but not yet in moderate or severe ARDS.

Key facts

Study ID

NCT04361253

Run by

Brigham and Women's Hospital

People needed

45

Starts

2020-04-30

Expected to finish

2021-06-30

Last updated by the study team

2021-08-13

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >1 year.
• Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.
• Meets institutional criteria for admission to hospital for COVID-19.
• Admitted to ICU or non-ICU floor within 5 days of enrollment.
• PaO2/FiO2 >200 mmHg if intubated.
• Patient or LAR able to provide informed consent.

You may not qualify if…

• Previous treatment with convalescent plasma for COVID-19.
• Current use of investigational antiviral therapy targeting SARS-CoV-2.
• History of anaphylactic transfusion reaction.
• Clinical diagnosis of acute decompensated heart failure.
• Objection to blood transfusion.

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.